A team of researchers affiliated with multiple entities in the Netherlands and one in Switzerland reports that a vaccine targeting a certain protein is effective in treating multiple types of cancers in several kinds of animals. In their paper published in the journal Nature Communications, the group describes the protein they discovered that is unique to cancer tumors and the vaccine they developed to treat patients.
In 2006, the same research team found that a protein called vimentin is produced in cancerous tumors and exists only in the blood that feeds such tumors. Subsequent work showed that the protein assisted with the creation of new blood vessels that enable tumor growth and that it also played a role in turning off the immune response. The researchers then developed a vaccine that would prevent the creation of vimentin inside tumors. They then tested the vaccine, called Griffioen, on several different laboratory animals with skin, brain and colorectal cancer and found varying degrees of success. Most recently, they tested it with dogs that had developed bladder cancer independently.
The researchers treated 35 of the dogs with their vaccine. Half of them survived to the end of the 400-day test period, and two of them fully recovered. They also treated one of their older pet dogs who had developed bone cancer and was expected not to live very long. The tumors disappeared and the dog returned to normal health soon thereafter.
The researchers conclude that their testing provides further proof that vimentin blocks the immune system and promotes the development of new blood vessels in tumors. And blocking it, they note, appears to be an effective therapy for the treatment of tumors. They note that thus far, they have seen no side effects with administration of Griffioen and report that more testing is required before clinical trials in humans can begin.
More information:
Judy R. van Beijnum et al, Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy, Nature Communications (2022). DOI: 10.1038/s41467-022-30063-7
Let us know if there is a problem with our content
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page.
For general inquiries, please use our contact form.
For general feedback, use the public comments section below (please adhere to guidelines).
Thank you for taking time to provide your feedback to the editors
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Donate and enjoy an ad-free experience
We keep our content available to everyone.
Consider supporting Science X's mission by getting a premium account.
This article has been reviewed according to Science X's editorial process
and policies.
Editors
have highlighted the following attributes while ensuring the content's credibility:
Medical Xpress is a web-based medical and health news service that is part of the renowned Science X network.
Based on the years of experience as a Phys.org medical research channel, started in April 2011, Medical Xpress became a separate website.
Medical Xpress is a part of Science X network.
With global reach of over 5 million monthly readers and featuring dedicated websites for hard sciences, technology, smedical research and health news,
the Science X network is one of the largest online communities for science-minded people.